– 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on trial as of data cutoff, ...
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...
Kura Oncology announces oral presentation of ziftomenib trial results for R/R NPM1-m AML at ASCO 2025, with investor event. Kura Oncology and Kyowa Kirin have announced that an abstract detailing the ...
Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
Kura Oncology (KURA) and Kyowa Kirin announced the U.S. Food and Drug Administration has granted full approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia with a ...
New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results